SLC5A2 and hydrops fetalis: The SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure) trial evaluated the effect of early initiation of sotagliflozin following an episode of decompensated HF on CV outcomes in patients with T2DM.49 Unlike other selective SGLT2 inhibitors routinely used in HF and T2DM, sotagliflozin is a nonselective SGLT1 receptor (predominantly found in the gastrointestinal tract) and SGLT2 receptor antagonist.